Cargando…

Identification of M(pro) inhibitors of SARS-CoV-2 using structure based computational drug repurposing

The recent outbreak of COVID-19, caused by the novel pathogen SARS-coronavirus 2 (SARS-CoV-2) is a severe health emergency. In this pandemic, drug repurposing seems to be the most promising alternative to identify effective therapeutic agents for immediate treatment of infected patients. The present...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nath, Virendra, Rohini, A., Kumar, Vipin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483991/ https://www.ncbi.nlm.nih.gov/pubmed/34611467 http://dx.doi.org/10.1016/j.bcab.2021.102178

Ejemplares similares

Computational repurposing of asthma drugs as potential inhibitors of SARS-CoV-2 M(pro)
por: Hussain, A., et al.
Publicado: (2022)

Drug repurposing and computational modeling for discovery of inhibitors of the main protease (M(pro)) of SARS-CoV-2
por: Silva, José Rogério A., et al.
Publicado: (2021)

Identification of SARS-CoV-2 inhibitors through phylogenetics and drug repurposing
por: Mishra, Anamika, et al.
Publicado: (2022)

Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M(pro) Protease
por: Tejera, Eduardo, et al.
Publicado: (2020)

Repurposing and computational design of PARP inhibitors as SARS-CoV-2 inhibitors
por: Rampogu, Shailima, et al.
Publicado: (2023)

Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods
por: Unni, Sruthi, et al.
Publicado: (2020)

Computational Repurposing of Drugs and Natural Products Against SARS-CoV-2 Main Protease (M(pro)) as Potential COVID-19 Therapies
por: Piplani, Sakshi, et al.
Publicado: (2022)

Drug repurposing against SARS-CoV-2 using computational approaches
por: Kumar, Sumit, et al.
Publicado: (2022)

An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors
por: Trezza, Alfonso, et al.
Publicado: (2020)

Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors
por: Chiou, Wei-Chung, et al.
Publicado: (2021)

Computational guided approach for drug repurposing against SARS-CoV-2
por: Anand, Jigisha, et al.
Publicado: (2021)

Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M(pro)
por: Balaramnavar, Vishal M., et al.
Publicado: (2020)

Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)

Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 M(pro)
por: Wang, Zhengyuan, et al.
Publicado: (2021)

M(pro)-targeted anti-SARS-CoV-2 inhibitor-based drugs
por: She, Zhuxin, et al.
Publicado: (2023)

Discovery of PL(pro) and M(pro) Inhibitors for SARS-CoV-2
por: Puhl, Ana C., et al.
Publicado: (2023)

Identification of potential inhibitors of SARS-CoV-2 S protein–ACE2 interaction by in silico drug repurposing
por: Tristán-Flores, Fabiola E, et al.
Publicado: (2021)

Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach
por: Behera, Santosh Kumar, et al.
Publicado: (2021)

Correction: Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M(pro)
por: Balaramnavar, Vishal M., et al.
Publicado: (2020)

Computational approaches for drug repositioning and repurposing to combat SARS-CoV-2 infection
por: Panda, Subhamay, et al.
Publicado: (2022)

Computational guided drug repurposing for targeting 2′-O-ribose methyltransferase of SARS-CoV-2
por: Sharma, Kedar, et al.
Publicado: (2020)

Structure-based computational screening of 470 natural quercetin derivatives for identification of SARS-CoV-2 M(pro) inhibitor
por: Kakhar Umar, Abd., et al.
Publicado: (2023)

Identification of SARS-CoV-2–induced pathways reveals drug repurposing strategies
por: Han, Namshik, et al.
Publicado: (2021)

Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen
por: Kuzikov, Maria, et al.
Publicado: (2021)

In Silico Identification of Potential Inhibitors of the SARS-CoV-2 Nucleocapsid Through Molecular Docking-Based Drug Repurposing
por: Afreen, Rukhsar, et al.
Publicado: (2022)

The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CL(pro) In Vitro
por: Eberle, Raphael J., et al.
Publicado: (2021)

Computational investigation of natural compounds as potential main protease (M(pro)) inhibitors for SARS-CoV-2 virus
por: Patel, Chirag N., et al.
Publicado: (2022)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study
por: Baby, Krishnaprasad, et al.
Publicado: (2021)

Rapamycin: Drug Repurposing in SARS-CoV-2 Infection
por: Patocka, Jiri, et al.
Publicado: (2021)

Multi-Targeted Approaches and Drug Repurposing Reveal Possible SARS-CoV-2 Inhibitors
por: Alanazi, Khalid Mashay, et al.
Publicado: (2021)

Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2
por: Ku, Keun Bon, et al.
Publicado: (2020)

Integrated computational approach towards repurposing of antimalarial drug against SARS-CoV-2 main protease
por: Gogoi, Neelutpal, et al.
Publicado: (2022)

Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing
por: Krishnamoorthy, Pandikannan, et al.
Publicado: (2021)

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen
por: Rodon, Jordi, et al.
Publicado: (2021)

Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations
por: Lazniewski, Michal, et al.
Publicado: (2022)

Identification of Trypanosoma cruzi Polyamine Transport Inhibitors by Computational Drug Repurposing
por: Reigada, Chantal, et al.
Publicado: (2019)

Inhibition of the main protease of SARS-CoV-2 (M(pro)) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds
por: Antonopoulou, Io, et al.
Publicado: (2022)

Repurposing of anti-lung cancer drugs as multi-target inhibitors of SARS-CoV-2 proteins: An insight from molecular docking and MD-simulation study
por: Reza, Rahimasoom, et al.
Publicado: (2022)

Computationally driven discovery of SARS-CoV-2 M(pro) inhibitors: from design to experimental validation
por: El Khoury, Léa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tmn7rg5ebnq4vbnpph9nbvqqr2